Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

SOTYKTU

DEUCRAVACITINIB

Standard Dose
6MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview SOTYKTU is listed in Drugs@FDA under application 214958 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient DEUCRAVACITINIB Form and strength TABLET;ORAL - 6MG Sponsor BRISTOL Submission history Latest submission status date: 2026-03-06 00:00:00.

Structured Monograph

Clinical summary

Approval overview SOTYKTU is listed in Drugs@FDA under application 214958 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient DEUCRAVACITINIB Form and strength TABLET;ORAL - 6MG Sponsor BRISTOL Submission history Latest submission status date: 2026-03-06 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.